Background: Noninvasive perinatal testing is a new method of screening for aneuploidy called cell-free DNA (cfDNA). Fetal fraction (FF) plays a crucial role in assessing the reliability of aneuploidy detection through noninvasive perinatal testing.

Objective: We aimed to investigate the association between the amount of FF in cfDNA testing and adverse pregnancy outcomes.

 Materials and Methods: This cohort study was conducted on 619 singleton pregnant women who were candidates for cfDNA testing and were referred to the perinatology clinics of Shariati hospital and Arash Women’s hospital, both affiliated with Tehran University of Medical Sciences, Tehran, Iran from March 2019 to June 2020. The FF was extracted from the cfDNA test results, and the participants were followed until delivery.

Results: A total of 619 singleton pregnant women with a mean ± SD age and FF of 34.4 ± 4.85 and 8.39 ± 3.95, respectively, participated in the study. A significant association between maternal age and FF was not found (p = 0.12). A lower FF was associated with a rise in the incidence of gestational diabetes mellitus (p = 0.02) and a higher FF was associated with a rise in the incidence of fetal growth restriction (p < 0.001). However, high or low FF was not associated with pre-eclampsia, premature rupture of membranes, birth weight, or delivery time. No significant association was found between FF and multiple of the median of pregnancy-associated plasma protein-A and free β-human chorionic gonadotropin.

Conclusion: The amount of FF may be considered a predictor of certain adverse pregnancy outcomes. Therefore, maternity care should be performed more carefully for women with high or low FF.

Keywords: Noninvasive prenatal testing, Cell-free DNA, Pre-eclampsia.

[1] Hui L, Bianchi DW. Fetal fraction and noninvasive prenatal testing: What clinicians need to know. Prenat Diagn 2020; 40: 155–163.

[2] Duan H-L, Li J, Wang W-J, Cram DS, Liu W, Cao P-X, et al. Cell-free DNA test for pathogenic copy number variations: A retrospective study. Taiwan J Obstet Gynecol 2021; 60: 1066–1071.

[3] Mousavi S, Shokri Z, Bastani P, Ghojazadeh M, Riahifar S, Nateghian H. Factors affecting low fetal fraction in fetal screening with cell-free DNA in pregnant women: A systematic review and meta-analysis. BMC Pregnancy Childbirth 2022; 22: 918.

[4] Yuan X, Zhou L, Zhang B, Wang H, Yu B, Xu J. Association between low fetal fraction of cell free DNA at the early second-trimester and adverse pregnancy outcomes. Pregnancy Hypertens 2020; 22: 101–108.

[5] Hestand MS, Bessem M, van Rijn P, de Menezes RX, Sie D, Bakker I, et al. Fetal fraction evaluation in non-invasive prenatal screening (NIPS). Eur J Hum Genet 2019; 27: 198–202.

[6] Hou Y, Yang J, Qi Y, Guo F, Peng H, Wang D, et al. Factors affecting cell-free DNA fetal fraction: Statistical analysis of 13,661 maternal plasmas for non-invasive prenatal screening. Hum Genom 2019; 13: 62.

[7] Becking EC, Wirjosoekarto SA, Scheffer PG, Huiskes JV, Remmelink MJ, Sistermans EA, et al. Low fetal fraction in cell-free DNA testing is associated with adverse pregnancy outcome: Analysis of a subcohort of the TRIDENT-2 study. Prenat Diagn 2021; 41: 1296–1304.

[8] Shook LL, Clapp MA, Roberts PS, Bernstein SN, Goldfarb IT. High fetal fraction on first trimester cell-free DNA aneuploidy screening and adverse pregnancy outcomes. Am J Perinatol 2020; 37: 8–13.

[9] Scheffer PG, Wirjosoekarto SA, Becking EC, Weiss MM, Bax CJ, Oepkes D, et al. Association between low fetal fraction in cell-free DNA testing and adverse pregnancy outcome: A systematic review. Prenat Diagn 2021; 41: 1287–1295.

[10] Chan N, Smet ME, Sandow R, da Silva Costa F, McLennan A. Implications of failure to achieve a result from prenatal maternal serum cell-free DNA testing: A historical cohort study. BJOG 2018; 125: 848–855.

[11] Gerson KD, Truong S, Haviland MJ, O’Brien BM, Hacker MR, Spiel MH. Low fetal fraction of cell-free DNA predicts placental dysfunction and hypertensive disease in pregnancy. Pregnancy Hypertens 2019; 16: 148–153.

[12] Krishna I, Badell M, Loucks TL, Lindsay M, Samuel A. Adverse perinatal outcomes are more frequent in pregnancies with a low fetal fraction result on noninvasive prenatal testing. Prenatal Diagn 2016; 36: 210–215.

[13] Zhao Ch, Tynan J, Ehrich M, Hannum G, McCullough R, Saldivar JS, et al. Detection of fetal subchromosomal abnormalities by sequencing circulating cell-free DNA from maternal plasma. Clin Chem 2015; 61: 608–616.

[14] Dugoff L, Barberio A, Whittaker PG, Schwartz N, Sehdev H, Bastek JA. Cell-free DNA fetal fraction and preterm birth. Am J Obstet Gynecol 2016; 215: 231.

[15] Colley E, Devall AJ, Williams H, Hamilton S, Smith P, Morgan NV, et al. Cell-free DNA in the investigation of miscarriage. J Clin Med 2020; 9: 3428.

[16] Golbasi H, Bayraktar B, Golbasi C, Omeroglu I, Adiyaman D, Alkan KO, et al. Association between fetal fraction of cell-free DNA and adverse pregnancy outcomes. Arch Gynecol Obstet 2024; 310: 1037–1048.

[17] Sifakis S, Koukou Z, Spandidos DA. Cell-free fetal DNA and pregnancy-related complications. Mol Med Rep 2015; 11: 2367–2372.

[18] Hopkins MK, Koelper N, Bender W, Durnwald C, Sammel M, Dugoff L. Association between cell-free DNA fetal fraction and gestational diabetes. Prenat Diagn 2020; 40: 724–727.

[19] Scott FP, Menezes M, Palma-Dias R, Nisbet D, Schluter P, da Silva Costa F, et al. Factors affecting cell-free DNA fetal fraction and the consequences for test accuracy. J Matern Fetal Neonatal Med 2018; 31: 1865–1872.

[20] Deng C, Liu J, Liu S, Liu H, Bai T, Jing X, et al. Maternal and fetal factors influencing fetal fraction: A retrospective analysis of 153,306 pregnant women undergoing noninvasive prenatal screening. Front Pediatr 2023; 11: 1066178.